Qiagen NV (QIA)-Medical Equipment-Deals and Alliances Profile

Qiagen NV (QIA)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME2456D
  • |
  • Pages: 140
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen's sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company's product portfolio includes consumable products, automated solutions for sample collection, and open and target specific assays. Qiagen also supplies diagnostic test kits and assays for human and veterinary molecular diagnostics. The company serves animal pathogens and genotyping, cancer research, and environmental water testing, among other sectors. Qiagen offers solutions to pharmaceutical and biotechnology companies, and research institutions. It has operations across the Americas; Europe, the Middle East, Africa, and Asia Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Qiagen NV, Medical Equipment, Deals By Year, 2011 to YTD 2017 8

Qiagen NV, Medical Equipment Deals By Type, 2011 to YTD 2017 9

Qiagen NV, Medical Equipment, Deals By Region, 2011 to YTD 2017 10

Qiagen NV, Medical Equipment, Deals By Market, 2011 to YTD 2017 11

Qiagen NV, Medical Equipment, Deals Summary, 2011 to YTD 2017 12

Qiagen NV, Medical Equipment, Deal Details 17

Asset Purchase 17

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 17

Venture Financing 18

Exosome Diagnostics Raises USD60 Million in Series B Financing Round 18

Protagen Raises USD12.5 Million in Venture Financing 19

Curetis Raises USD18 Million in Extended Series B Venture Financing 20

Exosome Diagnostics Raises US$27 Million In Series B Financing Round 22

Drug Response Dx Raises Funds Through First Round Of Venture Financing 23

Xagenic Raises US$10 Million In Series A Venture Financing 24

Partnerships 25

Qiagen Enters into Licensing Agreement with Johns Hopkins University 25

QIAGEN Enters into Licensing Agreement with Johns Hopkins University 25

Qiagen Enters into Licensing Agreement with MDxHealth 26

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 27

Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 28

Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 29

Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 30

IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 31

Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 32

Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 33

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 34

QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 34

Orion Genomics Enters Into Licensing Agreement With QIAGEN 35

Mayo Medical Labs Enters Into Licensing Agreement With Qiagen 36

Epigenomics Enters Into Research Licensing Agreement With QIAGEN 37

Epigenomics Announces Option Licensing Agreement With QIAGEN 38

DiaSorin Enters into Agreement with QIAGEN 39

Qiagen Forms Joint Venture with Maccura Biotech 40

Singulex Enters into Agreement with Qiagen 40

Sophia Genetics Enters into Agreement with Qiagen 41

Qiagen Enters into Agreement with Genohm 42

CareDx to Partner with Qiagen 42

Qiagen Enters into Partnership with Therawis Diagnostics 43

CosmosID Enters into Agreement with Qiagen 44

NanoString Technologies Enters into Co-Development Agreement with HalioDx 44

Qiagen Enters into Agreement with 10X Genomics 45

Qiagen Enters into Co-Development Agreement with Array BioPharma 46

Qiagen Forms Joint Venture with Biotype Diagnostics 47

Qiagen Enters into Agreement with Hitachi High-Technologies 47

Qiagen Enters into Agreement with GATC Biotech 48

Tokai Pharma Expands Agreement with Qiagen 49

Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 50

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 51

Qiagen Enters into Co-Development Agreement with Novartis 51

Qiagen Enters into Co-Development Agreement with Astellas Pharma 52

AstraZeneca Enters into Co-Development Agreement with Qiagen 53

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 54

Maverix Biomics Extends Co-Marketing Agreement With Qiagen 55

Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 55

Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 56

Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 57

Clovis Oncology Enters Into Co-Development Agreement With Qiagen 58

Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 59

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 61

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 62

PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 63

Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 64

Qiagen Enters Into Co-Development Agreement With Eli Lilly 64

Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 65

Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 66

Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 67

Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 68

PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 69

Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 70

Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 71

QIAGEN Enters Into Co-Development Agreement With Insight Genetics 71

QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 72

QIAGEN Enters Into Co-Development Agreement With Eli Lilly 73

Qiagen Enters Into Co-Development Agreement With Pfizer 74

IPSOGEN Enters Into Distribution Agreement With Sysmex 75

Olerup Enters Into Co-Marketing Agreement With QIAGEN 76

EyeSense Enters Into An Agreement With QIAGEN 77

Inserm Transfert Enters into Licensing Agreement with HalioDx 77

Transgenomic Expands Licensing Agreement with Exiqon 78

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 79

Equity Offering 80

Exiqon Completes Private Placement Of Shares For US$2.6 Million 80

Debt Offering 81

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 81

Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 81

Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 82

Exiqon Completes Private Placement Of Bonds For US$3 Million 83

Asset Transactions 84

Diatherix Labs Acquires Tem-PCR Patent From Qiagen 84

Acquisition 85

Qiagen Acquires OmicSoft 85

Qiagen Acquires Exiqon for up to USD102.4 Million 85

Qiagen Acquires MO BIO Labs 87

Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 88

Qiagen Acquires CLC bio, Bioinformatics Software Company 88

Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 89

Qiagen Completes Acquisition Of Additional 26.7% Stake In Ipsogen For US$30 Million 90

Qiagen Completes Acquisition Of Cellestis 92

Qiagen NV-Key Competitors 94

Key Employees 95

Locations And Subsidiaries 96

Head Office 96

Other Locations & Subsidiaries 96

Recent Developments 100

Financial Announcements 100

May 02, 2017: QIAGEN reports results for first quarter 2017 100

Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 102

Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 106

Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017 109

Apr 27, 2016: QIAGEN Reports Results for First Quarter of 2016 112

Feb 02, 2016: QIAGEN Reports Results for Fourth Quarter and Full-Year 2015 115

Jan 10, 2016: QIAGEN Announces Preliminary Results for Full-Year 2015 and Provides 2016 Outlook 119

Corporate Communications 120

Jul 04, 2016: Exiqon Nomination of candidates for the supervisory board 120

Government and Public Interest 121

Mar 30, 2017: QIAGEN joins CANCER-ID consortium for liquid biopsy workflows 121

Product News 122

Apr 03, 2017: QIAGENs GeneReader NGS System gains further validation in oncology research applications with new independent performance review data 122

Nov 22, 2016: QIAGEN and CosmosID Launch New Plugin for Metagenomics Analysis 123

Oct 20, 2016: QIAGEN launches QIAscout for single-cell isolation 124

Oct 10, 2016: QIAGEN launches high-throughput solutions for human ID databases 125

Jul 27, 2016: QIAGEN launches Digital NGS solutions with unique Molecular Index Technology to reliably detect all genetic variation 126

May 19, 2016: QIAGEN Bioinformatics Continues to Set the Standard With Hereditary Disease Solution 127

Apr 14, 2016: QIAGEN launches streamlined bioinformatics for RNA sequencing of liquid biopsies 128

Feb 15, 2016: Multi-center Study Confirms Value of QIAGEN's QuantiFERON-TB Gold Plus 129

Feb 11, 2016: QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing 130

Jan 26, 2016: QIAGEN to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage 131

Other Significant Developments 132

Jan 30, 2017: QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England 132

Nov 09, 2016: QIAGENs GeneReader NGS System streamlines data management for labs 133

Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017 134

Sep 29, 2016: QIAGEN and ICMP to develop first NGS workflow for identification of missing persons 135

Jun 21, 2016: QIAGEN Joins Consortium to Map Microbial Genomes in 54 Cities 136

Jun 01, 2016: Horizon Discovery Groups Molecular Reference Standards integrated into QIAGEN GeneReader NGS System 137

Feb 02, 2016: New agreements underscore QIAGENs leadership in bioinformatics 138

Appendix 139

Methodology 139

About GlobalData 139

Contact Us 139

Disclaimer 139

List of Figures

Qiagen NV, Medical Equipment, Deals by Type, 2011 to YTD 2017 1

Qiagen NV, Medical Equipment, Deals By Year, 2011 to YTD 2017 1

Qiagen NV, Medical Equipment, Deals By Region, 2011 to YTD 2017 1

Qiagen NV, Medical Equipment, Deals By Market, 2011 to YTD 2017 1

Qiagen NV, Medical Equipment, Deals By Year, 2011 to YTD 2017 9

Qiagen NV, Medical Equipment, Deals by Type, 2011 to YTD 2017 10

Qiagen NV, Medical Equipment, Deals By Region, 2011 to YTD 2017 11

Qiagen NV, Medical Equipment, Deals by Market, 2011 to YTD 2017 12

List of Tables

Qiagen NV, Medical Equipment, Key Facts, 2016 1

Qiagen NV, Medical Equipment, Deals Summary, 2011 to YTD 2017 1

Qiagen NV, Medical Equipment, Deals By Year, 2011 to YTD 2017 9

Qiagen NV, Medical Equipment Deals By Type, 2011 to YTD 2017 10

Qiagen NV, Medical Equipment, Deals By Region, 2011 to YTD 2017 11

Qiagen NV, Deals By Market, 2011 to YTD 2017 12

Qiagen NV, Medical Equipment, Deals Summary, 2011 to YTD 2017 13

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18

Exosome Diagnostics Raises USD60 Million in Series B Financing Round 19

Protagen Raises USD12.5 Million in Venture Financing 20

Curetis Raises USD18 Million in Extended Series B Venture Financing 21

Exosome Diagnostics Raises US$27 Million In Series B Financing Round 23

Drug Response Dx Raises Funds Through First Round Of Venture Financing 24

Xagenic Raises US$10 Million In Series A Venture Financing 25

Qiagen Enters into Licensing Agreement with Johns Hopkins University 26

QIAGEN Enters into Licensing Agreement with Johns Hopkins University 26

Qiagen Enters into Licensing Agreement with MDxHealth 27

Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 28

Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 29

Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 30

Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 31

IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 32

Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 33

Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 34

Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 35

QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 35

Orion Genomics Enters Into Licensing Agreement With QIAGEN 36

Mayo Medical Labs Enters Into Licensing Agreement With Qiagen 37

Epigenomics Enters Into Research Licensing Agreement With QIAGEN 38

Epigenomics Announces Option Licensing Agreement With QIAGEN 39

DiaSorin Enters into Agreement with QIAGEN 40

Qiagen Forms Joint Venture with Maccura Biotech 41

Singulex Enters into Agreement with Qiagen 41

Sophia Genetics Enters into Agreement with Qiagen 42

Qiagen Enters into Agreement with Genohm 43

CareDx to Partner with Qiagen 43

Qiagen Enters into Partnership with Therawis Diagnostics 44

CosmosID Enters into Agreement with Qiagen 45

NanoString Technologies Enters into Co-Development Agreement with HalioDx 45

Qiagen Enters into Agreement with 10X Genomics 46

Qiagen Enters into Co-Development Agreement with Array BioPharma 47

Qiagen Forms Joint Venture with Biotype Diagnostics 48

Qiagen Enters into Agreement with Hitachi High-Technologies 48

Qiagen Enters into Agreement with GATC Biotech 49

Tokai Pharma Expands Agreement with Qiagen 50

Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 51

Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 52

Qiagen Enters into Co-Development Agreement with Novartis 52

Qiagen Enters into Co-Development Agreement with Astellas Pharma 53

AstraZeneca Enters into Co-Development Agreement with Qiagen 54

Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 55

Maverix Biomics Extends Co-Marketing Agreement With Qiagen 56

Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 56

Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 57

Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 58

Clovis Oncology Enters Into Co-Development Agreement With Qiagen 59

Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 60

Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 62

Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 63

PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 64

Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 65

Qiagen Enters Into Co-Development Agreement With Eli Lilly 65

Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 66

Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 67

Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 68

Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 69

PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 70

Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 71

Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 72

QIAGEN Enters Into Co-Development Agreement With Insight Genetics 72

QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 73

QIAGEN Enters Into Co-Development Agreement With Eli Lilly 74

Qiagen Enters Into Co-Development Agreement With Pfizer 75

IPSOGEN Enters Into Distribution Agreement With Sysmex 76

Olerup Enters Into Co-Marketing Agreement With QIAGEN 77

EyeSense Enters Into An Agreement With QIAGEN 78

Inserm Transfert Enters into Licensing Agreement with HalioDx 78

Transgenomic Expands Licensing Agreement with Exiqon 79

Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 80

Exiqon Completes Private Placement Of Shares For US$2.6 Million 81

Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 82

Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 82

Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 83

Exiqon Completes Private Placement Of Bonds For US$3 Million 84

Diatherix Labs Acquires Tem-PCR Patent From Qiagen 85

Qiagen Acquires OmicSoft 86

Qiagen Acquires Exiqon for up to USD102.4 Million 86

Qiagen Acquires MO BIO Labs 88

Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 89

Qiagen Acquires CLC bio, Bioinformatics Software Company 89

Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 90

Qiagen Completes Acquisition Of Additional 26.7% Stake In Ipsogen For US$30 Million 91

Qiagen Completes Acquisition Of Cellestis 93

Qiagen NV, Key Competitors 95

Qiagen NV, Key Employees 96

Qiagen NV, Other Locations 97

Qiagen NV, Subsidiaries 97

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Qiagen NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16263
Site License
USD 500 INR 32525
Corporate User License
USD 750 INR 48788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com